

# Nickolas Papadopoulos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1022151/publications.pdf>

Version: 2024-02-01

91  
papers

26,617  
citations

50170

46  
h-index

49773

87  
g-index

97  
all docs

97  
docs citations

97  
times ranked

38020  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with <i>Fusobacterium nucleatum</i> and Its Subspecies <i>animalis</i> . <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 210-220.	1.1	19
2	Multicancer early detection test: Preclinical, translational, and clinical evidence—generation plan and provocative questions. <i>Cancer</i> , 2022, 128, 861-874.	2.0	7
3	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. <i>Frontiers in Medicine</i> , 2022, 9, 849222.	1.2	2
4	Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma. <i>ELife</i> , 2022, 11, .	2.8	4
5	An isogenic cell line panel for sequence-based screening of targeted anticancer drugs. <i>IScience</i> , 2022, 25, 104437.	1.9	2
6	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2261-2272.	13.9	337
7	Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA100-LBA100.	0.8	5
8	Prognostic significance of postsurgery circulating tumor <i>scp</i> DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	2.3	77
9	Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma. <i>Cancer</i> , 2021, 127, 1576-1589.	2.0	27
10	Bispecific antibodies targeting mutant <i>RAS</i> neoantigens. <i>Science Immunology</i> , 2021, 6, .	5.6	106
11	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	39
12	TCR $\beta$ chain-directed bispecific antibodies for the treatment of T cell cancers. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	30
13	Targeting a neoantigen derived from a common <i>TP53</i> mutation. <i>Science</i> , 2021, 371, .	6.0	194
14	Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2021, 160, 2043-2054.e2.	0.6	17
15	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	3.9	88
16	Targeting public neoantigens for cancer immunotherapy. <i>Nature Cancer</i> , 2021, 2, 487-497.	5.7	79
17	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. <i>Nature Biotechnology</i> , 2021, 39, 1220-1227.	9.4	40
18	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33

#	ARTICLE	IF	CITATIONS
19	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. <i>Nature Communications</i> , 2021, 12, 5271.	5.8	17
20	Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. <i>Nature Communications</i> , 2020, 11, 3644.	5.8	55
21	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2441-2453.	1.1	5
22	Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4858-4863.	3.3	50
23	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. <i>Science</i> , 2020, 369, .	6.0	351
24	Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. <i>Recent Results in Cancer Research</i> , 2020, 215, 163-180.	1.8	26
25	629â€¦Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody. , 2020, , .		0
26	A multimodality test to guide the management of patients with a pancreatic cyst. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	129
27	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1710.	3.4	383
28	An engineered antibody fragment targeting mutant $\beta$ -catenin via major histocompatibility complex I neoantigen presentation. <i>Journal of Biological Chemistry</i> , 2019, 294, 19322-19334.	1.6	15
29	Applications of liquid biopsies for cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	151
30	Direct Detection and Quantification of Neoantigens. <i>Cancer Immunology Research</i> , 2019, 7, 1748-1754.	1.6	40
31	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1118.	3.4	152
32	Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. <i>Modern Pathology</i> , 2019, 32, 1544-1550.	2.9	45
33	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
34	GENE-01. THE MUTATIONAL LANDSCAPE OF PRIMARY CHORDOMAS AND THEIR SENSITIVE DETECTION IN PLASMA ctDNA BY MULTIPLE NEXT GENERATION SEQUENCING TECHNOLOGIES. <i>Neuro-Oncology</i> , 2019, 21, vi97-vi97.	0.6	0
35	Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. <i>Human Pathology</i> , 2019, 85, 1-9.	1.1	28
36	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	6.1	234

#	ARTICLE	IF	CITATIONS
37	Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINES). Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1871-1876.	3.3	48
38	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	6.0	1,872
39	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	5.8	178
40	Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma. Nature Communications, 2018, 9, 5410.	5.8	30
41	Precancerous neoplastic cells can move through the pancreatic ductal system. Nature, 2018, 561, 201-205.	13.7	96
42	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	2.8	118
43	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. Journal of Clinical Oncology, 2018, 36, 3516-3516.	0.8	19
44	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, e16206-e16206.	0.8	4
45	A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 145-152.	2.2	34
46	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nature Genetics, 2017, 49, 358-366.	9.4	316
47	Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4733-4738.	3.3	12
48	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	13.9	451
49	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	3.3	438
50	Diagnostic potential of tumor DNA from ovarian cyst fluid. ELife, 2016, 5, .	2.8	30
51	Identification of novel noncoding transcripts in telomerase-negative yeast using RNA-seq. Scientific Reports, 2016, 6, 19376.	1.6	8
52	High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 427-434.	1.4	38
53	Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9846-9851.	3.3	178
54	Evaluating the evaluation of cancer driver genes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14330-14335.	3.3	325

#	ARTICLE	IF	CITATIONS
55	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	5.8	1,036
56	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. <i>Cancer Discovery</i> , 2016, 6, 166-175.	7.7	282
57	Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 265-274.	0.7	80
58	Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. <i>Human Pathology</i> , 2016, 53, 8-13.	1.1	31
59	High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. <i>Modern Pathology</i> , 2016, 29, 511-515.	2.9	34
60	Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. <i>Gastroenterology</i> , 2016, 150, 931-943.	0.6	208
61	Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. <i>Clinical Cancer Research</i> , 2015, 21, 1944-1950.	3.2	85
62	Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9967-9972.	3.3	41
63	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	0.6	376
64	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	5.8	372
65	Genetic Classification of Gliomas: Refining Histopathology. <i>Cancer Cell</i> , 2015, 28, 9-11.	7.7	40
66	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9704-9709.	3.3	317
67	Vitamin C selectively kills <i>KRAS</i> and <i>BRAF</i> mutant colorectal cancer cells by targeting GAPDH. <i>Science</i> , 2015, 350, 1391-1396.	6.0	722
68	Mutation of the <i>TERT</i> promoter, switch to active chromatin, and monoallelic <i>TERT</i> expression in multiple cancers. <i>Genes and Development</i> , 2015, 29, 2219-2224.	2.7	168
69	Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300.	0.8	87
70	Intraductal papillary mucinous neoplasm in a neonate with congenital hyperinsulinism and a de novo germline SKI1 gene mutation. <i>Pancreatology</i> , 2015, 15, 194-196.	0.5	8
71	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. <i>Cancer Discovery</i> , 2015, 5, 43-51.	7.7	1,180
72	Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool. <i>Journal of Clinical Oncology</i> , 2015, 33, 518-518.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	5.8	3,665
74	Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 15-24.	1.5	91
75	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11774-11779.	3.3	578
76	Epigenetic remodelling and dysregulation of DLGAP4 is linked with early-onset cerebellar ataxia. <i>Human Molecular Genetics</i> , 2014, 23, 6163-6176.	1.4	19
77	Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2014, 124, 881-885.	1.2	44
78	DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES. <i>Neuro-Oncology</i> , 2014, 16, iii7-iii7.	0.6	50
79	Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. <i>Nature Genetics</i> , 2014, 46, 1170-1172.	9.4	247
80	The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. <i>Cancer Research</i> , 2014, 74, 3381-3389.	0.4	207
81	Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11015-11015.	0.8	10
82	Cancer Genome Landscapes. <i>Science</i> , 2013, 339, 1546-1558.	6.0	6,507
83	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers. <i>Science Translational Medicine</i> , 2013, 5, 167ra4.	5.8	264
84	FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing. <i>PLoS ONE</i> , 2012, 7, e41162.	1.1	65
85	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . <i>Science</i> , 2011, 333, 1154-1157.	6.0	1,568
86	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21188-21193.	3.3	585
87	Serial Assessment of Human Tumor Burdens in Mice by the Analysis of Circulating DNA. <i>Cancer Research</i> , 2007, 67, 9364-9370.	0.4	147
88	The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. <i>Nature Biotechnology</i> , 2006, 24, 985-995.	9.4	124
89	Frequent HIN-1 Promoter Methylation and Lack of Expression in Multiple Human Tumor Types. <i>Molecular Cancer Research</i> , 2004, 2, 489-494.	1.5	46
90	Conversion Technology and Cancer Predispositions. , 2003, 223, 415-424.		0

#	ARTICLE	IF	CITATIONS
91	CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-cox vara-pericarditis syndrome. <i>Nature Genetics</i> , 1999, 23, 319-322.	9.4	286